Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Firms Seek to List R&D Arms, but Funding Risks Remain (India)

This article was originally published in PharmAsia News

Executive Summary

A number of large Indian drug makers are preparing to list their research and development sectors as a separate unit on the India stock exchange. Both Nicolas Piramal India Ltd. And Ranbaxy Laboratories have been vocal about the likelihood of listed R&D units in their futures. This move may not be the best course of action, according to KPMG International's John Morris. In his opinion, the Indian stock market is not mature enough to provide companies with the $100 million to $200 million in funding they are going to need. According to KPMG estimates Indian drug companies will spend $500 million on research and development by 2010 and $1.2 billion by 2015. He says Indian companies looking to raise that kind of major cash should look to private equity investors. He suggests partnerships with funds in West Asia or Russia might be particularly profitable. Another option, according to Morris, is to partner with large international pharmaceutical companies. Whether he is correct remains to be seen. So far, Sun Pharma Advanced Research Ltd. is the only research unit posted on the Bombay Stock Exchange. Currently, the company is trading at Rs83.25, 4.48 percent below its initial public offering price. (Click here for more

You may also be interested in...



Trump’s Last-Minute Push for Faster COVID-19 Vaccine Could Jeopardize Uptake

White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.

A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.

After EUA, US Will Ship Only Half Of Doses For Pfizer, Moderna COVID-19 Vaccines

Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel